GSK

News

CHMP decision levels the playing field for GSK's RSV jab

GSK's RSV vaccine is poised for EU approval in all adults aged 18 and over, bringing it into line with rival shots from Pfizer and Moderna.

News

Gloved hand punches a karate pad held up

GSK unit and AnaptysBio trade lawsuits over Jemperli

A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.

News

GSK pumps £45m into antimicrobial resistance projects

GSK has revealed the six projects it will fund with the Fleming Initiative on antimicrobial resistance, set up with Imperial College London last year.

News

Medical group advises against leucovorin for autism

The American Academy of Paediatrics has warned against leucovorin as a treatment for autism, citing a lack of evidence on safety and efficacy.

News

Specialty meds lift GSK's outlook in Walmsley's swan song

Emma Walmsley's last set of financial results as GSK's chief executive has gone swimmingly, allowing the company to raise its 2025 forecasts.

News

GSK strikes again, adding COPD candidate in $745m deal

In its second pipeline-expanding deal in 24 hours, GSK has licensed rights to a drug for COPD from US biotech Empirico for $85m upfront.

CHMP decision levels the playing field for GSK's RSV jab

GSK unit and AnaptysBio trade lawsuits over Jemperli

GSK pumps £45m into antimicrobial resistance projects

Medical group advises against leucovorin for autism

Specialty meds lift GSK's outlook in Walmsley's swan song

GSK strikes again, adding COPD candidate in $745m deal

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

GSK

Editor's Picks